Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression

Prostate

Volumn 69, Issue 11, 2009, Pages 1176-1187

  Pang, Bo ^a,b   Zhang, Hui ^a   Wang, Jian ^a   Chen, Wen Zheng ^c   Li, Shan Hu ^a   Shi, Qing Guo ^a   Liang, Rei Xia ^a   Xie, Bang Xiang ^a   Wu, Rui Qin ^a   Qian, Xiao Long ^a   Yu, Lan ^a   Li, Qi Man ^a   Huang, Cui Fen ^a   Zhou, Jian Guang ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Androgen independent; Prostate cancer; Proteomics; Reactive oxygen species; Ubiquitous mitochondrial creatine kinase

Indexed keywords

ANDROGEN; MITOCHONDRIAL CREATINE KINASE; PROSTATE SPECIFIC ANTIGEN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN BINDING PROTEIN 2; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL STRAIN LNCAP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; AMINO ACID SEQUENCE; CELL PROLIFERATION; CULTURE MEDIUM; DISEASE COURSE; MALE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CREATINE KINASE, MITOCHONDRIAL FORM; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MOLECULAR SEQUENCE DATA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; TUMOR MARKERS, BIOLOGICAL;

EID: 67650587125     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20969     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008.
2. Isaacs JT. Apoptosis: Translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000;92(17):1367-1369.
3. Prowse AB, McQuade LR, Bryant KJ, Van Dyk DD, Tuch BE, Gray PP. A proteome analysis of conditioned media from human neonatal fibroblasts used in the maintenance of human embryonic stem cells. Proteomics 2005;5(4):978-989.
4. Andersen H, Jensen ON, Eriksen EF. A proteome study of secreted prostatic factors affecting osteoblastic activity: Identification and characterisation of cyclophilin A. Eur J Cancer 2003;39(7):989-995.
5. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen- independence and osseous metastasis. Prostate 2000;44(2):91-103.
6. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C 4-2 prostate cancer models. Prostate 2006;66(9):971-986.
7. Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA. Gene expression in the LNCaP human prostate cancer progression model: Progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 2006;244(2):274-288.
8. Wang J, Ying T, Wang H, Shi Z, Li M, He K, Feng E, Wang J, Yuan J, Li T, Wei K, Su G, Zhu H, Zhang X, Huang P, Huang L. 2-D reference map of Bacillus anthracis vaccine strain A16R proteins. Proteomics 2005;5(17):4488-4495.
9. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31(24):e154.
10. Pulukuri SM, Rao JS. Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 2007;67(14):6637-6646.
11. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA, Arnold RS. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005;62(2):200-207.
12. Meyer LE, Machado LB, Santiago AP, da-Silva WS, De Felice FG, Holub O, Oliveira MF, Galina A. Mitochondrial creatine kinase activity prevents reactive oxygen species generation: Antioxidant role of mitochondrial kinase-dependent ADP recycling activity. J Biol Chem 2006;281(49):37361-37371.
13. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992;281(Pt 1):21-40.
14. Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006;1762(2):164-180.
15. Stallings RL, Olson E, Strauss AW, Thompson LH, Bachinski LL, Siciliano MJ. Human creatine kinase genes on chromosomes 15 and 19, and proximity of the gene for the muscle form to the genes for apolipoprotein C2 and excision repair. Am J Hum Genet 1988;43(2):144-151.
16. Haas RC, Korenfeld C, Zhang ZF, Perryman B, Roman D, Strauss AW. Isolation and characterization of the gene and cDNA encoding human mitochondrial creatine kinase. J Biol Chem 1989;264(5):2890-2897.
17. Onda T, Uzawa K, Endo Y, Bukawa H, Yokoe H, Shibahara T, Tanzawa H. Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 2006;94(5):698-709.
18. Nakagawa H, Kida N, Maesa M, Wakuta Y, Ohtaki S. An abnormal isoenzyme of creatine kinase in the serum of a patient with metastatic carcinoma: Identity with mitochondrial creatine kinase. Clin Chem 1982;28(4 Pt 1):723-725.
19. Heinz JW, O'Donnell NJ, Lott JA. Apparent mitochondrial creatine kinase in the serum of a patient with metastatic cancer to the liver. Clin Chem 1980;26(13):1908-1911.
20. Hoag GN, Franks CR, DeCoteau WE. Creatine kinase isoenzymes in serum of patients with cancer of various organs. Clin Chem 1978;24(9):1654.
21. Kanemitsu F, Kageoka T, Kira S. Mitochondrial creatine kinase with atypical pI values detected in serum of a patient with ovarian hepatoid yolk sac tumor. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783(1):191-1197.
22. Ruiz Ginés MA, Calafell Mas MF, Ruiz Ginés JA, Fernández Rodríguez E. Macro creatine kinase: Illness marker. Practical guide for the management. An Med Interna 2006;23(6):272-275.
23. Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 2007;213(1):261-268.
24. DeLuca M, Hall N, Rice R, Kaplan NO. Creatine kinase isozymes in human tumors. Biochem Biophys Res Commun 1981;99:189-195.
25. Tsung SH. Creatine kinase activity and isoenzyme pattern in various normal tissues and neoplasms. Clin Chem 1983;29(12):2040-2043.
26. Kanemitsu F, Kawanishi I, Mizushima J, Okigaki T. Mitochondrial creatine kinase as a tumor-associated marker. Clin Chim Acta 1984;138(2):175-183.
27. Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, Kornacker B, Staratschek-Jox A, Diehl V, Wolf J. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer 2001;94(4):513-519.
28. Hatano E, Tanaka A, Kanazawa A, Tsuyuki S, Tsunekawa S, Iwata S, Takahashi R, Chance B, Yamaoka Y. Inhibition of tumor necrosis factor-induced apoptosis in transgenic mouse liver expressing creatine kinase. Liver Int 2004;24:384-393.
29. Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ 2003;10(7):761-771.
30. Zamzami N, Kroemer G. The mitochondrion in apoptosis: How Pandora's box opens. Nat Rev Mol Cell Biol 2001;2(1):67-71.
31. Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006;10(3):175-176.
32. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51(3):794-798.
33. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68(6):1777-1785.
34. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer JR, Gotoh A. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 2006;25(10):1437-1445.
35. Wu WS. The signaling mechanismof ROS in tumor progression. Cancer Metastasis Rev 2006;25(4):695-705.
36. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA. Upregulation of Akt3 in estrogen receptor deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-21532.
37. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non neoplastic tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-6578.
38. Clerkin JS, Naughton R, Quiney C, Cotter TG. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 2008;266:30-36.